Market closed
Corvus Pharmaceuticals/$CRVS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Ticker
$CRVS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
28
Website
CRVS Metrics
BasicAdvanced
$521M
Market cap
-
P/E ratio
-$1.01
EPS
1.04
Beta
-
Dividend rate
Price and volume
Market cap
$521M
Beta
1.04
52-week high
$9.28
52-week low
$1.30
Average daily volume
844K
Financial strength
Current ratio
0.925
Quick ratio
0.902
Total debt to equity
2.853
Management effectiveness
Return on assets (TTM)
-28.30%
Return on equity (TTM)
-200.48%
Valuation
Price to book
40.9
Price to tangible book (TTM)
40.9
Price to free cash flow (TTM)
-20.58
Growth
Earnings per share change (TTM)
58.26%
3-year earnings per share growth (CAGR)
78.83%
What the Analysts think about CRVS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.
CRVS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CRVS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CRVS News
AllArticlesVideos
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
GlobeNewsWire·1 week ago
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
GlobeNewsWire·4 weeks ago
Corvus Pharmaceuticals: The Market Likes The Story
Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Corvus Pharmaceuticals stock?
Corvus Pharmaceuticals (CRVS) has a market cap of $521M as of December 12, 2024.
What is the P/E ratio for Corvus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Corvus Pharmaceuticals (CRVS) stock is 0 as of December 12, 2024.
Does Corvus Pharmaceuticals stock pay dividends?
No, Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next Corvus Pharmaceuticals dividend payment date?
Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Corvus Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.